Non-cytotoxic and sublethal paclitaxel treatment potentiates the sensitivity of cultured ovarian tumor SKOV-3 cells to lysis by lymphokine-activated killer cells

Anticancer Research

Volumn 27, Issue 2, 2007, Pages 841-850

  Kim, Seng Law ^a,b,c   Chen, Hung Chang ^a   Liao, Shuen Kuei ^a,d  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b TUNGS' TAICHUNG METROHARBOR HOSPITAL   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Apoptosis; Chemo immunotherapy; ICAM 1; LAK cells; Ovarian carcinoma; Paclitaxel; SKOV 3 cell line

Indexed keywords

CISPLATIN; LYMPHOKINE; PACLITAXEL;

ARTICLE; CANCER INHIBITION; CELL CULTURE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; KILLER CELL; LYSIS; OVARY CANCER; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL GROWTH PROCESSES; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; EPITHELIAL CELLS; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; K562 CELLS; KILLER CELLS, LYMPHOKINE-ACTIVATED; MIDDLE AGED; OVARIAN NEOPLASMS; PACLITAXEL;

EID: 34247117387     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Tong AW, Seamour B, Lawson JM, Ordonez G, Vukelja S, Hyman W, Richards D, Stein L, Maples PB and Nemunaitis J: Cellular immune profile of patients with advanced cancer before and after taxane treatment. Am J Clin Oncol 23: 463-472, 2000.
2. Spencer CM and Faulds D: Paclitaxel: a review of its pharmacodynamic pharmacokinetic properties and therapeutic potential in the treatment of cancer. Drug 48: 794-847, 1994.
3. Wani MC, Taylor HL, Wall ME, Coggon P and McPhail AT: Plant antitumor agent. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevilolis. J Am Chem Soc 93: 2325-2327, 1971.
4. Schiff PB and Horwitz SB: Tubulin: a target for chemotherapeutic agents. In: Molecular Actions and Targets for Cancer Chemotherapeutic Agents. Satorelli AC, Lazo JS, Bertino JR (eds.). New York, Academic Press, pp. 483-507, 1981.
5. Lamendola DE, Duan Z, Yusuf RZ and Seiden MV: Molecular description of evolving paclitaxel resistance in the SKOV-3 human ovarian carcinoma cell line. Cancer Res 62: 2200-2205, 2003.
6. Sugimura M, Sagae S, Ishioka S-I, Nishioka Y, Tsukada K and Kudo R: Mechanisms of paclitaxel-induced apoptosis in an ovarian cancer cell line and its paclitaxel-resistant clone. Oncology 66: 53-61, 2004.
7. Rosenberg SA: Lymphokine-activated killer cells: a new approach to immunotherapy of cancer. J Natl Cancer Inst 75: 595-603, 1985.
8. Rosenberg SA, Lotze MT, Muul LM, Leitman S and Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, Seipp CA, Simpson C and Reichert CM: Observaation on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Eng J Med 313: 1485-1492, 1985.
9. West HY, Tauer KW, Yannelli JR, Marshall GD, Orr DW, Thurman GB and Oldham RK: Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Eng J Med 316: 898-905, 1987.
10. Rosenberg SA, Lotz MT, Muul LM, Chang AE, Avis FP, Leitman S, Linenan M, Robertson CG, Lee RE, Rubin JI, Seipp CA, Simpson CG and White DE: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high dose interleukin-2 alone. N Eng J Med 316: 889-897, 1987.
11. Ortaldo JR, Masson A and Overton R: Lymphokine-activated killer cells: analysis of progenitors and effectors. J Exp Med 164: 1193-1205, 1986.
12. Michch E: Relationship between chemotherapy and immunotherapy: a brief overview. In: Rationale of Biological Response Modifiers in Cancer Treatment. Tsubura E, Urushizaki I, Sune S and Kaneko Y (eds.). Excerpta Medica, Amsterdam/Priceton/Geneva/Tokyo, pp. 105-115, 1982.
13. Perng Y-P, Lin C-C, Perng I-M, Shen Y-C, Chuang C-K and Liao S-K: Culture medium induced morphological changes of melanoma cells associated with change in sensitivity to lysis by lymphokine-activated killer cells. Cancer Biother Radiopharmaceut 12: 317-331, 1997.
14. Pross H, Baines M, Rubin P and Patterson M: Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. IX. The quantitation of natural killer cell activity. J Clin Immunol 1: 51-63, 1991.
15. Lin C-W, Yasumura S, Suminami Y, Sung M-W, Nagashima S, Stanson J and Whiteside TL: Constitutive production of IL-2 by human carcinoma cells, expression of IL-2 receptor, and tumor cell growth. J Immunol 133: 4805-4816, 1995.
16. Frixen UH, Nehrens J, Schs M, Eberle G, Voss B, Warde A, Lorothea D and Birchmeier W: E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol 113: 173-185, 1991.
17. Kudo Y, Kitajiro S, Ogawa I, Hiraoka M, Sargolzaeu S, Keikhaee MR, Sato S, Miyauchi M and Takata T: Invasion and metastasis of oral cancer cells require methylation of E-cadherin and/or degradation of membranous β-catenin. Clin Cancer Res 10: 5455-5463, 2004.
18. Chang CT-R, Weng W-H, Chou AS-B, Chuang C-K, Porwit-McDonald A, Pang S-T, Larsson C and Liao S-K: Immunophenotypic and molecular cytogenetic features of the cell line UP-LN1 established from a lymph node metastasis of a poorly-differentiated carcinoma. Anticancer Res 25: 683-692, 2005.
19. Multhoff G, Pfister K, Botzer C, Jorday A, Scholz R, Schmetzer H, Burostatahler R and Hiddemann W: Adoptive transfer of human natural killer cells in mice with severe combined immunodeficiency inhibits growth of HSP70-expressing tumors. Int J Cancer 88: 791-797, 2000.
20. Botzler C, Issels R and Multhoff G: Heat-shock protein 72 cell surface expression on human lung carcinoma cells is associated with an increase sensitivity to lysis mediated by adherent natural killer cells. Cancer Immunol Immunother 43: 226-230, 1996.
21. Anichini A, Mortariani R, Supino R and Parmiani G: Human melanoma cells with high suscepitibility to cell-mediated lysis can be identified on the basis of ICAM-1 phenotype. VLA profile and invasive ability. Int J Cancer 46: 508-515, 1990.
22. Naganuma H, Kiessling R, Patarroyo M, Hansson M, Hangretinger R and Gronberg A: Increased susceptibility of IFN-γ-treated neuroblastoma cells to lysis by lymphokine-activated killer cells: Participation of ICAM-1 induction on target cells. Int J Cancer 47: 527-532, 1991.
23. Rivoltini L, Catteretti G, Arienti F, Mastroianni A, Melani C, Colombo MP and Parmiani G: The high lysability by LAK cells of colon-carcinomas resistant to doxorubicin is associated with a high expression of ICAM-1, LFA-3 and NCA and a less-differentiated phenotype. Int J Cancer 47: 746-754, 1991.
24. Gwin JL, Gircel-Taylor C, Taylor DD and Eisenberg B: Role of LFA-3, ICAM-1, and MHC class I on the sensitivity of human tumor cells to LAK cells. J Surg Res 60: 129-136, 1996.
25. Moore KW, de Waal Malefyt R, Coffman RL and O'Garra A: Interleukin-10 and the interlekin-10 receptor. Annu Rev Immunol 19: 683-765, 2001.
26. Abrahams VM, Straszewski SL, Kamsteeg M, Hanczaruk B, Schwartz PE, Rutherford TJ and Mor G: Epithelial ovarian cancer cells secrete functional Fas ligand. Cancer Res 63: 5573-5581, 2003.
27. Zou W: Immunosuppressive networks in the tumor environment and their therapeutic relevance. Nat Rev Cancer 5: 263-274, 2005.
28. Cokos G and Conejo J-R: The tumor microenvironment. Regulation of antitumor immunity and implications for immunotherapy. In: Immunotherapy of Cancer. ML Disis (ed.). Humana Press, Totowa, New Jersey, pp. 285-301, 2006.
29. Lake RA and Robinson BWS: Immunotherapy and chemotherapy - a practical partnership. Nat Rev Cancer 5: 397-405, 2005.
30. Shi YJ, Ren HY, Cen XN, Zhu Q and Yu JR: Immunological effector cells enhance apoptodsis induced by adriamycin in a multidrug-resistant human breast cancer cell line. Zhonghua Zhong Liu Za Zhi 26: 188-191, 2006 (in Chinese).
31. Itoh K, Pellis NR and Balch CM: Monocyte-dependent, serum born suppressor of induction of lymphokine-activated killer cells in lymphocytes from melanoma patients. Cancer Immunol Immunother 29: 57-62, 1989.
32. Riley LB, Pellis NR, Schantz SP, Freedman RS, Balch CM and Itoh K: Humoral modulation of lymphokine-activated killer (LAK)-cell induction in humans: IgG-related and non-IgG inhibitors in sera from cancer patients. Int J Cancer 40: 785-791, 1990.
33. Tanner J and Tosato G: Impairment of natural killer functions by interleukin-6 increases lymphoblastoid cell tumorigenicity in athymic mice. J Clin Invest 88: 239-247, 1991.
34. Sarin A, Haddad EK and Henkart PA: Caspase dependence of target cell damage induced by cytotoxic lymphocytes. J Immunol 161: 2810-2816, 1998.
35. Catalfamo M and Henkart PA: Perforin and the granule exocytosis cytotoxixity pathway. Curr Opin Immunol 15: 522-527, 2003.
36. Zarcone D, Viale G, Cerruti G, Marloni W, Ferrini S, Moretta A and Grossi CE: Differentiation of tumor cell lines and their susceptibility to non-MHC-restricted cytotoxic cells. J Immunol Res 1: 87-93, 1989.
37. Grimm EA, Ramsy KM, Mazumder A, Wilson DJ, Djeu JY and Rosenberg SA: Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus derived lymphocytes, and natural killer cell. J Exp Med 157: 884-897, 1983.
38. Ortaldo JR, Mason A and Overton R: Heterogeneity of cell populations from human peripheral blood mediating lymphokine-stimulated cytotoxicity. In: Natural Immunity, Cancer and Biological Modification. Lotzova L, Herberman RB (eds.). Basel, Karger, pp. 114-123, 1986.
39. Park S-J, Wu C-H, Gordon JD, Zhong X, Emami A and Safa AR: Taxol induces caspase-10-dependent apoptosis. J Biol Chem 279: 51057-51067, 2004.
40. Yamaguchi Y, Hironaka K, Okawaki M, Okita R, Matsuura K, Ohshita A and Toge T: HER2-specific cytotoxic activity of lymphokine-activated killer cells in the presence of trastuzumab. Anticancer Res 25: 827-832, 2005.
41. Muul LM, Director EP, Hyatt C and Rosenberg SA: Large scale production of human lymphokine-activated killer cells for use in adoptive immunotherapy. J Immunol Meth 88: 265-272, 1986.
42. Lacerna LV, Hester J, Pineda AA, Burgstaler E and Klein HG. Clinical/Technical challenges in adoptive cellular immunotherapy (ACI): the role of cytaphoresis. In: Adoptive Cellular Immunotherapy of Cancer. Stevenson HG (ed.). New York, Marcel Dekker, pp. 175-189, 1989.
43. Yannelli JR, Thurman GB, Dickerson SG, Mrowca A, Sharp E and Oldham RK: An improved method for the generation of human lymphokine-activated killer cells. J Immunol Meth 100: 137-145, 1987.